• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

michael.roche@unimelb.edu.au

Credentials


Position
Deputy Head, Lewin Lab
Department of Infectious Diseases
Education
PhD
Monash University
PhD
Monash University
Bachelors Degree
Deakin University
Bachelors Degree (Honours)
Monash University
ORCID

0000-0001-8819-0096

Dr Michael Roche

Deputy Head, Lewin Lab
Department of Infectious Diseases

123 Scholarly works
15 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Targeting rapidly cycling receptors CD2 and CD7 increases nanoparticle delivery to primary CD4 T cells.
    DOI: 10.1038/s41467-026-74981-2
  • 2026

    Journal article

    HIV Promoters Isolated from Brain and Peripheral Tissue of Virally Suppressed PWH Are Phylogenetically and Functionally Similar
    DOI: 10.3390/ijms27073185
  • 2026

    Journal article

    Methaneseleninic acid, a circadian-modulating agent, reactivates latent HIV-1 infection without cellular activation or proliferation
    DOI: 10.1128/jvi.01983-25
  • 2026

    Journal article

    The effect of combining HIV latency reversal with inhibition of phosphoinositide-3 kinases or B-cell lymphoma-2 on the HIV reservoir
    DOI: 10.1371/journal.ppat.1013923
  • 2022

    Research grants (international)

    Targetted Delivery of LNP-encapsulated CRISPR/Cas9 for HIV Elimination
  • 2021

    Research grants (international)

    Delaney AIDS Research Enterprise to Find a Cure (DARE 3.0) - (2021-2026) - SUBAWARD 7
  • 2019

    Research contracts (non-grants)

    Victorian HIV Cure Consortium - Detecting Sites of Persistent HIV and Latency Reversal With Vorinostat and 64Cu Radiolabeled 3BNC117
Michael Roche

RECENT SCHOLARLY WORKS

  • 2025

    Journal article

    Limitations and use of the Morpheus-V5 dual reporter virus in assessing interventions that target HIV latency
    DOI: 10.1016/j.jviromet.2025.115236
  • 2025

    Journal article

    The impact of acute stress on the HIV reservoir: a prospective interventional trial
    DOI: 10.1016/j.jve.2025.100613
  • 2025

    Journal article

    Hepatitis B surface antigen is upregulated by HIV Tat in an HIV–hepatitis B virus co-infection model system
    DOI: 10.1128/spectrum.00809-25
  • 2025

    Journal article

    CRISPR/Cas9 for achieving postintervention HIV control
    DOI: 10.1097/COH.0000000000000963
  • 2025

    Journal article

    Host-directed approaches in the pursuit of a cure for HIV
    DOI: 10.1016/j.antiviral.2025.106216
  • 2025

    Journal article

    Efficient mRNA delivery to resting T cells to reverse HIV latency
    DOI: 10.1038/s41467-025-60001-2

RECENT PROJECTS

  • 2025

    Research grants (international)

    Direct and Indirect Targeting of HIV Tat for Selective RNA Degradation and Protein Suppression
  • 2026

    Research grants (ARC, NHMRC, MRFF)

    Leveraging mRNA and Lipid Nanoparticle Technology to Develop a Cure for HIV

Acknowledgement of Country

We acknowledge Aboriginal and Torres Strait Islander people as the Traditional Owners of the unceded lands on which we work, learn and live. We pay respect to Elders past, present and future, and acknowledge the importance of Indigenous knowledge in the Academy.

Read about our Indigenous priorities

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Campus locations  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia

facebookIconlinkedinIconinstagramIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy

CRICOS number: 00116K     ABN: 84 002 705 224